The Effect of Drugs From Novartis and Sanofi-Aventis on Mortality Rates Will Drive Prescription Decisions in Hypertension Treatment
Posted on: Wednesday, 2 April 2008, 09:01 CDT
WALTHAM, Mass., April 2, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on mortality rates (all-cause mortality) is the attribute that most influences primary care physicians' (PCPs) prescribing decisions in the treatment of hypertension. Clinical data and expert opinion shows that Novartis's Tekturna HCT, Novartis's Exforge and Sanofi-Aventis's ilepatril all have advantages in this attribute over sales- leading amlodipine.
The new report entitled Hypertension: Many Treatment Options, but None Stands Out in the Efficacy Measures Most Important to PCPs finds that of the emerging therapies in this market, fixed-dose combinations and ilepatril will be most efficacious at lowering blood pressure. Surveyed PCPs indicate that they would prescribe each of Tekturna HCT, aliskiren/valsartan and ilepatril to 10 percent of their patients with hypertension.
The report also finds that, through 2016, there are no therapies in development that will displace Exforge as the clinical gold standard treatment for hypertension. Exforge has achieved its current gold standard status owing to its enhanced efficacy and safety when compared to other hypertension treatments.
"Experts we interviewed indicated that fixed-dose combinations, including Exforge, are the most effective currently available agents at lowering both systolic and diastolic blood pressure," said Jeremy Goldman, M.D., analyst at Decision Resources. "As a result of its effect on reducing blood pressure, Exforge is also likely to reduce complications of hypertension, such as myocardial infarction and stroke, to a greater degree than other currently marketed products."
About the Report
Hypertension: Many Treatment Options, but None Stands Out in the Efficacy Measures Most Important to PCPs is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Reportlinker Adds Push to Talk and Wireless Push Technologies Market Opportunities, Strategies, Shares, and Forecasts 2008 to 2014
- Experian CheetahMail Launches Emailresponsibly.com - a Two-way Knowledge-Sharing Resource for E-mail Marketers
- US Market for Minimally Invasive Treatment of Varicose Veins to Rise to More than $215 Million by 2013
- Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
- Ford Strengthens European Market Share In 2008, Becomes Second Best-Selling Brand
- A Drug That Improves Exercise Capacity By a Greater Percentage Than Tracleer Would Earn a 48 Percent Patient Share in the Pulmonary Arterial Hypertension Market
- China Witnessed a Fast Growth of Further Processing Of Corn in 2007 According To the Report 'China Corn & Corn Processing Products Market Review & Outlook Proposal 2007/2008'
- Push to Talk and Wireless Push Technologies Market Opportunities, Strategies, Shares, and Forecasts 2008 to 2014
- Worldwide Total Blade Server Markets At 52 Billion In 2008 Are Forecast To Reach 157 Billion Dollars By 2013
- 'Big Pharma' and Biotechnology Companies Boost U.S. Pulmonary Arterial Hypertension Markets
 |
 |
User Comments (0)
RSS Feeds